Enzym Group, a biotechnology company, and Kormotech, a global pet food producer — both part of the Vovk Family Business — are entering a new chapter of strategic development. On Thursday, May 22, 2025, the Vovk family officially introduced its International Supervisory Board, comprised of globally recognized experts in corporate governance, biotechnology, operations, reputation strategy, and commercial leadership. The Board’s role is to provide strategic guidance to both companies, rooted in global expertise, accountability, and a long-term vision for sustainable international growth.
Both companies are currently undergoing an ambitious transformation: entering new markets across Asia, the EU, the U.S., and Africa; launching innovative products; expanding production capabilities; and scaling biotech R&D. The family’s leadership is convinced that this trajectory requires a strong system of external strategic oversight — grounded in relevant international experience.
The International Supervisory Board has been operating since early 2024. It includes five independent members, each serving in a non-operational, strategic advisory capacity, and four representatives from the Vovk family.
Board Composition
Peter Therman – Chairman of the Board
Vice Chairman of Hartwall Capital and a sixth-generation member of one of Finland’s most prominent business families, Peter Therman brings a wealth of experience in family governance, investment oversight, and board leadership. He has served on the boards of SecuryCast Oy, Stockmann, Camfil, and the Finnish Family Business Network, and is widely regarded for his ability to bridge family values with future-focused business strategy.
Dr. Steffen Ernst – Innovation & Biotech Commercialization
A recognized pioneer in biotechnology and enzyme innovation, Dr. Steffen Ernst spent over two decades at Novozymes, where he held senior roles in global R&D and commercial development. He led the creation of Novozymes’ probiotic business through alliances with Bayer Animal Health, Adisseo, and Boehringer Ingelheim, scaling it into a global growth driver. A graduate of M.I.T. and co-founder of GreenSage Innovations, Dr. Ernst sits at the intersection of science, sustainability, and market impact—bringing world-class expertise in turning advanced biotech into scalable business.
Peter Ernsting – Supply Chain & Operational Excellence
With a distinguished career at Unilever, Carlsberg, and Accell Group, Peter Ernsting has led complex global supply chains, transformed operational models, and embedded sustainability into core business systems. His leadership of Carlsberg’s global operations team of 18,000 across 40 markets positions him as an invaluable guide for Vovk’s next phase of manufacturing and logistics development.
Alison Potts – Commercial Strategy & Marketing Leadership
Appointed to the Board in April 2025, Alison Potts brings over 35 years of leadership across global sales, finance, and marketing functions. Previously, she has held executive roles at Stella & Chewy's, Nestlé Health Science, Kraft, Diageo, Bacardi, and Cisco Brewers. She holds an MBA from the Jack Welch College of Business and is an alum of the London Business School Executive Program. Known for bridging commercial discipline with creative brand building, she has shaped go-to-market strategies and launched award-winning consumer products globally. Her expertise will guide the Vovk Family’s customer focus and global expansion strategy.
Nataliia Popovych – Ethics, Trust & Reputation Strategy
Founder of One Philosophy and co-founder of the Resilient Ukraine CSO, Nataliia Popovych is a leading voice in values-based leadership, strategic communications, and crisis resilience. Named to the ICCO Hall of Fame, she has advised governments, NGOs, and global corporations on strengthening public trust and social impact. Her guidance based on over 20 years of experience of working in Ukraine and the region, USA and Denmark, will ensure that Vovk’s growth is deeply rooted in responsibility, transparency, and societal contribution.
Olena Vovk – Chair of the Supervisory Board, Enzym Group
As co-owner of Enzym Group and Kormotech, Olena Vovk leads the transformation of Enzym Group from a yeast plant into one of Eastern Europe’s most resilient biotech companies. Since 2014, she has guided the company’s strategic shift toward innovation, science, and global markets. Olena sits on the academic and strategic boards of UCU Business School, shaping the next generation of ethical leadership in Ukraine.
Rostyslav Vovk – Chair of the Supervisory Board & CEO, Kormotech
As CEO of Kormotech, Rostyslav Vovk has scaled the company from a family startup into a top-50 global pet food producer. Under his leadership, Kormotech now sells in fiftye countries and operates a team of over 1,500 people. He is also a board member at Enzym Group and SUP (Association of Ukrainian Entrepreneurs), and co-founder of the initiatives like Save Pets of Ukraine and Patron Pets Center in Ukraine.
Yuliana Volk – Strategic Development, Kormotech
Family Representative on the Global Board
With a background in FMCG, hospitality, and media, Yuliana Vovk plays a key role in Kormotech’s global expansion. She led the company’s U.S. market entry, established its European presence, and drove its internal transformation into an English-speaking, export-focused business. As a member of the M&A and Art Direction Committees, Yuliana brings a strategic and brand-forward mindset to the Vovk Family Business portfolio.
Andriy Tsehelyk – CEO, Enzym Group
Family Representative on the Global Board
A longtime financial advisor to the Vovk Family Business and CEO of Enzym Group since 2018, Andriy Tsehelyk has played a pivotal role in transforming the company during the crisis. He built Enzym Group’s financial system from the ground up, led investment strategy, and ensured business continuity through blackouts and full-scale war. Thanks to his foresight and leadership, the company grew revenues by nearly 30% in 2022 while keeping operations fully active.
Leading with Purpose, Scaling with Integrity
The Vovk Family Business is entering a new phase of growth — expanding into Asia, the EU, the U.S., and Africa, launching products not yet available on the Ukrainian market, increasing production capacity, and scaling biotech R&D. To support this transformation, the companies are building not only strong teams, but also a system of external strategic oversight guided by global experience.
The new International Board reflects the family’s ambition to grow responsibly while staying rooted in long-term vision and values. With expertise in biotechnology, operations, stakeholder trust, and commercial strategy, the Board will help shape a resilient, future-ready business capable of navigating uncertainty — and thriving beyond it.
